AquaBounty Technologies Inc (AQB)

AquaBounty's stock experienced a significant drop in December 2024 due to the cessation of salmon-farming operations and a leadership change. The company reported increased net losses and decreased product revenue in its Full Year 2024 Financial Results. AquaBounty raised $1.15 million in February 2026 through common stock and pre-funded warrants. In April 2026, the company exchanged $4.3 million of high-interest Senior Notes into Series A Convertible Preferred Stock. In May 2026, AquaBounty reported a Q1 2026 net loss and expressed substantial doubt about its ability to continue as a going concern without new capital.

Information explicitly detailing demand seasonality for AquaBounty Technologies, Inc.'s products and services is not readily available. It is plausible that the demand for its specific product, AquAdvantage Salmon, might be less subject to the natural seasonal fluctuations typically associated with wild-caught fish.

AquaBounty Technologies, Inc. is a biotechnology and aquaculture company specializing in land-based fish farming, operating within the Health Technology sector. Their primary product is AquAdvantage Salmon, a genetically engineered Atlantic salmon designed for faster growth. The company uses land-based recirculating aquaculture systems to prevent disease, protect wild fish populations, and reduce carbon footprint.

AquaBounty Technologies, Inc. is headquartered in Maynard, Massachusetts, United States. Historically, the company operated aquaculture facilities in Prince Edward Island, Canada, and Indiana, USA. In July 2024, AquaBounty sold its Indiana grow-out farm and began winding down fish-rearing operations at its Canadian farm sites in December 2024. The Canadian subsidiary, including the broodstock farms on Prince Edward Island and the company's intellectual property for AquAdvantage salmon, was sold in March 2025. The company also had a partially constructed farm project in Pioneer, Ohio, but construction was paused due to increased costs, and AquaBounty is now pursuing strategic alternatives for this project, including selling related equipment. AquaBounty also previously operated a land-based incubation and grow-out facility in Panama.

AquaBounty's brand reputation has been negatively impacted by operational challenges and public perception of genetically modified organisms. The company has faced public skepticism and opposition to its bioengineered products. The stock price decline in December 2024 and ongoing financial difficulties have further contributed to a challenging brand perception.

AquaBounty Technologies, Inc. has a notable institutional ownership presence, including Renaissance Technologies Llc, Epiq Partners, Llc, Two Sigma Investments, Lp, BlackRock, Inc., Two Sigma Advisers, Lp, Geode Capital Management, Llc, Citadel Advisors Llc, Vanguard Group Inc, DRW Securities, LLC, and Susquehanna International Group, Llp. Randal J. Kirk is the largest individual shareholder.